Skip to search formSkip to main contentSkip to account menu

famitinib

An orally bioavailable receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Famitinib binds to and inhibits several RTKs… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

IndolesPyrroles
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

SHR1020

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Camrelizumab plus famitinib malate in patients with advanced renal cell cancer and unresectable urothelial carcinoma: A multicenter, open-label, single-arm, phase II trial.
5085Background: Camrelizumab (SHR-1210) is a humanised anti-PD-1 antibody. Famitinib malate is a tyrosine kinase inhibitor (TKI… 
2018
2018
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study
BackgroundFamitinib is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor… 
2016
2016
Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
Famitinib (SHR1020), a novel multi-targeted tyrosine kinase inhibitor, has antitumor activity against several solid tumors via… 
2016
2016
A phase 1b study of famitinib plus docetaxel as 2nd line setting in patients with metastatic non-squamous non-small cell lung cancer and EGFR wild type.
e20603Background: This phase Ib study was designed to evaluate the safety and efficacy of famitinib plus docetaxel in previously… 
Review
2016
Review
2016
[Metabolic research of domestically developed small molecule tyrosine kinase inhibitors].
Drug metabolism research plays an essential role in drug discovery and development. Great efforts have been made domestically to… 
2015
2015
Clinical efficacy of famitinib malate for treatment of metastatic renal cell carcinoma-a report of 9 cases
Objective To study the clinical effect of famitinib malate for treatment of metastatic renal cell carcinoma(mRCC).Methods Nine… 
2015
2015
TKI Famitinib Delays Progression in Advanced Colorectal Cancer
The TKI famitinib was associated with a significant PFS improvement in metastatic colorectal cancer patients, according to the… 
2014
2014
[Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
This study is to establish physiologically based pharmacokinetic (PBPK) models of famitinib in rat and monkey, and then to… 
2013
2013
A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens.
6026 Background: Famitinib is an oral, small molecular multiple tyrosine-kinase inhibitor (TKI), targeting stem cell growth… 
2011
2011
Tolerability of famitinib malate:the preliminary results from phase I clinical trial
Objective: To establish the safety profile and recommended dose of famitinib malate for phase Ⅱ clinical trials,and to evaluate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)